[1]
|
张钰群, 袁勇贵. 2020年抑郁症研究进展回顾[J]. 中华医学信息导报, 2021, 36(4): 11-12.
|
[2]
|
Al-Harbi, K.S. (2012) Treatment-Resistant Depression: Therapeutic Trends, Challenges, and Future Directions. Patient Prefer Adherence, 6, 369-388. https://doi.org/10.2147/PPA.S29716
|
[3]
|
Trevino, K., McClintock, S.M., McDonald Fischer, N., et al. (2014) Defining Treatment-Resistant Depression: A Comprehensive Review of the Literature. Annals of Clinical Psychi-atry, 26, 222-232.
|
[4]
|
Vollenweider, F.X., Leenders, K.L., Oye, I., et al. (1997) Differential Psychopathology and Patterns of Cerebral Glucose Utilisation Produced by (S)- and (R)-Ketamine in Healthy Volunteers Using Positron Emis-sion Tomography (PET). European Neuropsychopharmacology, 7, 25-38. https://doi.org/10.1016/S0924-977X(96)00042-9
|
[5]
|
余乐, 王清秀. 麻醉药抗抑郁作用的研究进展[J]. 同济大学学报(医学版), 2021, 42(4): 574-580.
|
[6]
|
Mahase, E. (2021) Depression: EU Approves Expanded Use of Es-ketamine for Rapid Reduction of Symptoms. BMJ, 372, n398. https://doi.org/10.1136/bmj.n398
|
[7]
|
Swainson, J., Thomas, R.K., Archer, S., et al. (2019) Esketamine for Treatment Resistant Depression. Expert Review of Neurothera-peutics, 19, 899-911. https://doi.org/10.1080/14737175.2019.1640604
|
[8]
|
Castrén, E. and Kojima, M. (2017) Brain-Derived Neurotrophic Factor in Mood Disorders and Antidepressant Treatments. Neurobiology of Disease, 97, 119-126. https://doi.org/10.1016/j.nbd.2016.07.010
|
[9]
|
Garcia, L.S., Comim, C.M., Valvassori, S.S., et al. (2008) Acute Administration of Ketamine Induces Antidepressant-Like Effects in the Forced Swimming Test and Increases BDNF Levels in the Rat Hippocampus. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 140-144. https://doi.org/10.1016/j.pnpbp.2007.07.027
|
[10]
|
Derkach, V.A., Oh, M.C., Guire, E.S., et al. (2007) Regulatory Mechanisms of AMPA Receptors in Synaptic Plasticity. Nature Reviews Neuroscience, 8, 101-113. https://doi.org/10.1038/nrn2055
|
[11]
|
Holz, A., Mülsch, F., Schwarz, M.K., et al. (2019) Enhanced mGlu5 Signal-ing in Excitatory Neurons Promotes Rapid Antidepressant Effects via AMPA Receptor Activation. Neuron, 104, 338-352.e7.
https://doi.org/10.1016/j.neuron.2019.07.011
|
[12]
|
Zanos, P., Moaddel, R., Morris, P.J., et al. (2016) NMDAR In-hibition-Independent Antidepressant Actions of Ketamine Metabolites. Nature, 533, 481-486. https://doi.org/10.1038/nature17998
|
[13]
|
Pozzi, L., Pollak Dorocic, I., Wang, X., et al. (2014) Mice Lacking NMDA Receptors in Parvalbumin Neurons Display Normal Depression-Related Behavior and Response to Antidepres-sant Action of NMDAR Antagonists. PLoS ONE, 9, e83879. https://doi.org/10.1371/journal.pone.0083879
|
[14]
|
Zanos, P. and Gould, T.D. (2018) Mechanisms of Ketamine Ac-tion as an Antidepressant. Molecular Psychiatry, 23, 801-811. https://doi.org/10.1038/mp.2017.255
|
[15]
|
Aleksandrova, L.R., Phillips, A.G. and Wang, Y.T. (2017) Antidepres-sant Effects of Ketamine and the Roles of AMPA Glutamate Receptors and Other Mechanisms beyond NMDA Receptor Antagonism. Journal of Psychiatry & Neuroscience, 42, 222-229. https://doi.org/10.1503/jpn.160175
|
[16]
|
Cavalleri, L., Merlo Pich, E., Millan, M.J., et al. (2018) Ketamine Enhanc-es Structural Plasticity in Mouse Mesencephalic and Human iPSC-Derived Dopaminergic Neurons via AMPAR-Driven BDNF and mTOR Signaling. Molecular Psychiatry, 23, 812-823. https://doi.org/10.1038/mp.2017.241
|
[17]
|
Murrough, J.W., Iosifescu, D.V., Chang, L.C., et al. (2013) Antidepres-sant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial. The American Journal of Psychiatry, 170, 1134-1142.
https://doi.org/10.1176/appi.ajp.2013.13030392
|
[18]
|
Lee, E.E., Della Selva, M.P., Liu, A., et al. (2015) Ketamine as a Novel Treatment for Major Depressive Disorder and Bipolar Depression: A Systematic Review and Quantitative Meta-Analysis. General Hospital Psychiatry, 37, 178-184.
https://doi.org/10.1016/j.genhosppsych.2015.01.003
|
[19]
|
Yang, C., Shirayama, Y., Zhang, J.C., et al. (2015) R-Ketamine: A Rapid-Onset and Sustained Antidepressant without Psychotomimetic Side Effects. Translational Psychi-atry, 5, e632. https://doi.org/10.1038/tp.2015.136
|
[20]
|
Yang, C., Kobayashi, S., Nakao, K., et al. (2018) AMPA Receptor Activation-Independent Antidepressant Actions of Ketamine Metabolite (S)-Norketamine. Biological Psychiatry, 84, 591-600.
https://doi.org/10.1016/j.biopsych.2018.05.007
|
[21]
|
Murrough, J.W., Abdallah, C.G. and Mathew, S.J. (2017) Targeting Glutamate Signalling in Depression: Progress and Prospects. Nature Reviews Drug Discovery, 16, 472-486. https://doi.org/10.1038/nrd.2017.16
|
[22]
|
Singh, J.B., Fedgchin, M., Daly, E., et al. (2016) Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study. Biological Psychiatry, 80, 424-431.
https://doi.org/10.1016/j.biopsych.2015.10.018
|
[23]
|
Daly, E.J., Singh, J.B., Fedgchin, M., et al. (2018) Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry, 75, 139-148.
https://doi.org/10.1001/jamapsychiatry.2017.3739
|
[24]
|
Canuso, C.M., Singh, J.B., Fedgchin, M., et al. (2018) Ef-ficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Pa-tients at Imminent Risk for Suicide: Results of a Double- Blind, Randomized, Placebo-Controlled Study. The American Journal of Psychiatry, 175, 620-630.
https://doi.org/10.1176/appi.ajp.2018.17060720
|
[25]
|
Grunebaum, M.F., Galfalvy, H.C., Choo, T.H., et al. (2018) Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. The American Journal of Psychiatry, 175, 327-335. https://doi.org/10.1176/appi.ajp.2017.17060647
|
[26]
|
Kim, J., Farchione, T., Potter, A., et al. (2019) Esketamine for Treatment-Resistant Depression—First FDA-Approved Antidepressant in a New Class. The New England Journal of Medicine, 381, 1-4.
https://doi.org/10.1056/NEJMp1903305
|
[27]
|
李普乐, 康霞, 吕爽, 等. 艾司氯胺酮用于抑郁症治疗的研究进展[J]. 中华实用诊断与治疗杂志, 2021, 35(7): 750-752.
|
[28]
|
Bahr, R., Lopez, A. and Rey, J.A. (2019) Intranasal Esketamine (Spravato(TM)) for Use in Treatment-Resistant Depression in Conjunction with an Oral Antidepressant. PT, 44, 340-375.
|
[29]
|
Short, B., Fong, J., Galvez, V., et al. (2018) Side-Effects Associated with Ketamine Use in Depres-sion: A Systematic Review. The Lancet Psychiatry, 5, 65-78. https://doi.org/10.1016/S2215-0366(17)30272-9
|
[30]
|
Bossaller, N.A. and Shelton, R.C. (2020) Real-World Ap-proach to Managing Dysgeusia Following the Use of Esketamine Nasal Spray: A Case Report. Annals of General Psy-chiatry, 19, 13. https://doi.org/10.1186/s12991-020-00262-x
|
[31]
|
Dold, M., Bartova, L. and Kasper, S. (2020) Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Sec-ond-Generation Antipsychotic Treatment. International Journal of Neuropsychopharmacology, 23, 440-445. https://doi.org/10.1093/ijnp/pyaa034
|
[32]
|
Correia-Melo, F.S., Argolo, F.C., Araújo-de-Freitas, L., et al. (2017) Rapid Infusion of Esketamine for Unipolar and Bipolar Depression: A Retrospective Chart Review. Neuropsychiatric Disease and Treatment, 13, 1627-1632.
https://doi.org/10.2147/NDT.S135623
|
[33]
|
Sanacora, G., Frye, M.A., McDonald, W., et al. (2017) A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 74, 399-405. https://doi.org/10.1001/jamapsychiatry.2017.0080
|
[34]
|
冯若冰, 肖乐, 胡永东. 氯胺酮抗抑郁治疗临床研究进展[J]. 北京医学, 2019, 41(7): 595-597.
|
[35]
|
李嘉, 韩芳. 新型抗难治性抑郁症药艾司氯胺酮研究进展[J]. 牡丹江医学院学报, 2021, 42(5): 103-106.
|
[36]
|
Leal, G.C., Bandeira, I.D., Correia-Melo, F.S., et al. (2021) Intravenous Arketamine for Treatment-Resistant Depression: Open-Label Pilot Study. European Archives of Psychiatry and Clinical Neuroscience, 271, 577-582.
https://doi.org/10.1007/s00406-020-01110-5
|
[37]
|
范妮. 氯胺酮抗抑郁的临床研究[J]. 四川精神卫生, 2021, 34(3): 193-196.
|
[38]
|
Cullen, K.R., Amatya, P., Roback, M.G., et al. (2018) Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 28, 437-444.
https://doi.org/10.1089/cap.2018.0030
|